XOMA Royalty Corp XOMA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1986-06-06
XOMA Royalty Corp statistics & valuation
Market cap$738.6M
P / E23.3×
P / S14.2×
P / B8.8×
Dividend yield0.74%
Net margin60.8%
Return on equity37.8%
Net debt$13.5M
Enterprise value USD$752.2M
Earnings yield EBIT/EV1.5%
Return on capital4.8%
Graham number$12.38
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($12.38); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 21.8% | -140.3% | -879.5% | -288.9% | 45.9% | 42.3% | -21.1% | -318.1% | 32.3% | -1106.4% |
| Net margin | 60.8% | -48.5% | -858.2% | -283.8% | 41.4% | 45.3% | -10.8% | -251.8% | 27.7% | -962.1% |
| FCF margin | — | -48.3% | -382.0% | — | — | 34.3% | — | -238.7% | 5.1% | -606.5% |
| Return on assets | 11.6% | -6.2% | -17.4% | -12.2% | 9.5% | 10.6% | -2.1% | -20.9% | 32.5% | -186.7% |
| Return on equity | 37.8% | -22.3% | -46.0% | -13.8% | 11.1% | 15.4% | -4.5% | -71.0% | 252.3% | 113.4% |
| Debt / equity | 1.15× | 1.73× | 1.34× | 0.00× | — | 0.24× | 0.73× | 1.15× | 2.52× | -0.91× |
| Current ratio | 3.37 | 5.15 | 8.68 | 8.98 | 7.48 | 7.16 | 6.76 | 8.35 | 5.95 | 0.84 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.